Regulatory and safe-use considerations related to stability after opening of nonsterile dosage forms
Tóm tắt
The stability test after opening is conducted to establish an appropriate storage period during which the quality is maintained of multidose drug products that are opened and used repeatedly. While some of the regulatory agencies have provided guidelines for in-use stability study design, detailed guidelines covering various formulations are not provided. So, the guidelines are necessary to help the industry both understand and conduct stability studies. In addition, health-care professionals are required to provide patients or patient caregivers with information regarding the storage of medicines after opening. Furthermore, unless otherwise stated in marketing authorization, if the safety, efficacy, and quality of products are susceptible to inappropriate storage, then it is also necessary to prepare the related safe use guidelines. In this paper, trends in the stability after opening guidelines of international organizations and competent regulatory agencies were investigated. The safe use guidelines, such as storage period after opening for nonsterile preparations, were also reviewed. As a result of the study, regulatory guidelines for the formulation (product), target batch and testing time point, container closure system, and sample storage conditions of the in-use stability test are presented. Additionally, from the perspective of the safe use of pharmaceuticals, stability information to be recommended to patients and storage period after opening for each dosage form are also presented. Based on these presentations, we intend to prepare guidelines that pharmaceutical industry and health-care professionals can refer to in the field.
Tài liệu tham khảo
American Society of Health-System Pharmacists (1994) ASHP Technical Assistance Bulletin on Compounding Nonsterile Products in Pharmacies. Am J Health Syst Pharm 1994(51):1441–1448
European Medicines Agency (1998) Note for guidance on development pharmaceutics
European Medicines Agency (2001) Note for Guidance on In-use stability Testing of Human Medicinal Products
European Medicines Agency (2003) Note for guidance on stability testing: Stability testing of new drug substances and products
European Medicines Agency (2004) Guideline on stability testing: Stability testing of existing active substances and related finished products
Food and Drug Administration (2003) Guidance for Industry, Q1A(R2) Stability Testing of New Drug Substances and Products
Food and Drug Administration (2013) Guidance for Industry, ANDAs: Stability Testing of Drug Substances and Products.
Food and Drug Administration (2014) Guidance for Industry, ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers
Food and Drug Administration (2019) Guidance for Industry, ANDAs submissions—Content and format
International Conference on Harmonisation (1996) Stability testing: Photostability testing of New Drug Substances and Products Q1B Current Step 4 version
International Conference on Harmonisation (2003) Stability Testing of New Drug Substances and Products Q1A(R2) Current Step 4 version
International Pharmaceutical Regulation Programme (2020) Quality Working Group (QWG), Guidance for quality assessors—Drug products
Khan MM, Jiang B, Mazzeo A & Huynh-Ba K (2018) Stability challenges not addressed by harmonized guidance—AAPS workshop of the stability focus group, April 3rd- 4th, 2017 in Rockville, MD. AAPS Open 4
Matthews BR (1999) Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm 25:831–856
Ministry of Food and Drug Safety (2015a) The Pharmaceutical Affairs Act Article 21
Ministry of Food and Drug Safety (2015b) The Pharmaceutical Affairs Act Article 24
Ministry of Food and Drug Safety (2016a) Guideline on Stability Testing for Pharmaceuticals after Opening
Ministry of Food and Drug Safety (2016b) Enforcement Decree of the Pharmaceutical Affairs Act Article 15-6
Ministry of Health, Labour and Welfare (1960) Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices Article 9-3
Ministry of Health, Labour and Welfare (1961) Regulation for Enforcement of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices Article 15-13
Pharmaceuticals and Medical Devices Agency (2006) Stability test guidelines
NHS (2001) Storage, stability and in-use shelf-life guidelines for non-sterile medicines. NHS Specialist Pharmacy Services
NHS (2014) Good Practice Guidance Q: Guidance on the Expiry Dates and Storage of Medicines in Care Homes (with or without nursing). NHS Oxfordshire Clinical Commissioning Group
NHS (2017) Good Practice Guidance - Understanding Expiry Dates and Storage of Medicins in Care Homes. NHS Isle of Wight Clinical Commissioning Group
NHS (2019) Good Practice Guidance on Expiry Dates of Medication. NHS Rotherham Clinical Commissioning Group
NHS (2021a) Expiry Date of Medication after Opening. NHS Telford and Wrekin Clinical Commissioning Group
NHS (2021b) Care Homes—Good Practice Guidance on Expiry Dates of Medicines. NHS Gloucestershire Health and Care
Pharmaceutical Inspection Co-operation Scheme (2021) Guide to Good Manufacturing Practice for medicinal Products Part 1:9-15
French Society of Clinical Pharmacy (2013) Methodological guidelines for stability studies of hospital pharmaceutical preparation, Part 1: liquid preparations
Therapeutic Goods Administaration (2017) Stability testing for prescription medicines
United States Code (2008) Title 42 (The public health and welfare) 1396r-8 Payment for covered outpatient drugs
U.S. Pharmacopeial Convention (2018) General Chapter <1191> Stability considerations in dispensing practice
U.S. Pharmacopeial Convention (2020a) General Chapter <7> Labeling
U.S. Pharmacopeial Convention (2020b) General Chapter Pharmaceutical compounding-nonsterile preparations
World Health Organization (2018) Technical Report Series. No. 1010, Stability testing of active pharmaceutical ingredients and finished pharmaceutical products